National Institute for Health and Care Excellence (Nice)

The National Institute for Health and Care Excellence (NICE) is a UK organization that provides national guidance and advice to improve health and social care. It evaluates the clinical and cost-effectiveness of new and existing treatments, technologies, and interventions to inform decisions about their use within the National Health Service (NHS) in England. NICE's recommendations influence which treatments are available to NHS patients. Currently, NICE is newsworthy due to several recent developments. It has authorized the use of Veoza (fezolinetant), a drug that prevents hot flushes, for over 500,000 women in England on the NHS. Additionally, a UK-US medicines deal is under scrutiny, with critics fearing it could impact NHS funding, even as it expands access to some drugs. NICE's role in approving or rejecting treatments based on cost and efficacy remains crucial, particularly in areas like ADHD diagnosis and Alzheimer's therapies, where access to care and effective treatments are ongoing concerns.